Ginkgo Bioworks Holdings DNA
NYSE DNA
$6.93 -0.02 (-0.29%)
As of: Sep 4, 2026 · 11:51 AM EDT

Ginkgo Bioworks Holdings (DNA) Profit After Tax (2020 - 2026)

Ginkgo Bioworks Holdings' (DNA) quarterly Profit After Tax came in at -$82.6 million in Q1 2026, up 0.87% YoY from -$81.9 million in Q1 2025, and down 135.62% on a QoQ basis from $231.9 million in Q4 2025.

Analysis

Ginkgo Bioworks Holdings (DNA) Profit After Tax (2020 - 2026) Analysis & Trends

Ginkgo Bioworks Holdings (DNA) has 7 years of Profit After Tax data on file, last reported at -$82.6 million in Q1 2026.

  • Quarterly Profit After Tax rose 0.87% year-over-year to -$82.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.7 million (down 86.65% YoY) and the FY2025 annual result came in at $3.7 million, up 211.16% from the prior year.
  • Profit After Tax fell to -$82.6 million in Q1 2026, from $231.9 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of $437.4 million in Q4 2024 to a low of -$670.6 million in Q2 2022.
  • A 5-year average of -$180.8 million and a median of -$173.0 million in 2023 frame the typical range for Profit After Tax.
  • Annual changes were most pronounced in 2022 — Profit After Tax slumped 1143.15% — and 2024, when it jumped 306.63%.
  • Tracing DNA's Profit After Tax over 5 years: stood at -$175.5 million in 2022, then slipped by 20.65% to -$211.7 million in 2023, then jumped by 306.63% to $437.4 million in 2024, then plunged by 46.99% to $231.9 million in 2025, then slumped by 135.62% to -$82.6 million in 2026.
  • The last three Profit After Tax figures came in at -$82.6 million (Q1 2026), $231.9 million (Q4 2025), and -$80.8 million (Q3 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) PAT (Qtr)
1 Vertex Pharmaceuticals 140.22 Bn 132.37 Bn 2.84 Bn 1.10 Bn
2 Regeneron Pharmaceuticals 86.04 Bn 78.05 Bn 3.93 Bn 1.30 Bn
3 Argenx Se 63.70 Bn 58.52 Bn 1.37 Bn 472.00 Mn
4 Moderna 57.56 Bn 52.42 Bn 52.00 Mn -782.00 Mn
5 Revolution Medicines 44.05 Bn 44.05 Bn - -644.37 Mn
6 BeOne Medicines 40.16 Bn 35.06 Bn 1.53 Bn 237.01 Mn
7 Alnylam Pharmaceuticals 35.63 Bn 32.32 Bn 992.69 Mn 164.49 Mn
8 Royalty Pharma 28.63 Bn 27.79 Bn - 81.49 Mn
9 Insmed 27.73 Bn 26.57 Bn 358.27 Mn -16.62 Mn
10 Ginkgo Bioworks Holdings 430.38 Mn 345.84 Mn 18.44 Mn -57.32 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -57.32 Mn
Mar 31, 2026 -83.24 Mn
Dec 31, 2025 -80.75 Mn
Sep 30, 2025 -80.76 Mn
Jun 30, 2025 -60.30 Mn
Mar 31, 2025 -90.96 Mn
Dec 31, 2024 -109.60 Mn
Sep 30, 2024 -56.40 Mn
Jun 30, 2024 -217.35 Mn
Mar 31, 2024 -168.95 Mn
Dec 31, 2023 -211.43 Mn
Sep 30, 2023 -304.49 Mn
Jun 30, 2023 -173.32 Mn
Mar 31, 2023 -204.97 Mn
Dec 31, 2022 -167.80 Mn
Sep 30, 2022 -672.55 Mn
Jun 30, 2022 -670.57 Mn
Mar 31, 2022 -592.59 Mn
Dec 31, 2021 -1.61 Bn
Sep 30, 2021 -102.41 Mn